The FDA has classified as Class II an ongoing recall by Apollo Care, LLC of compounded semaglutide multi-dose vials across a wide range of strengths and concentrations, posted on 19 August 2026. The reason given is particulate matter, identified as nylon or polyamide and silk or proteinaceous-type material.
This is not a recall of licensed semaglutide. It concerns compounded product — semaglutide made up by a facility rather than supplied by the originator — and multi-dose vials of it, a presentation that does not exist in the licensed product. Class II means the defect may cause temporary or medically reversible harm, with serious harm unlikely; injected particulate matter of this kind carries a risk of local reaction and, with a proteinaceous material, of sensitisation.
The wider point is about where the drug came from. Compounded and grey-market GLP-1 receptor agonists proliferated during shortage, sold in vials with syringes and a dose chart rather than a pen, and quality control varies. Ask patients on semaglutide what device they use: someone drawing up from a multi-dose vial is almost certainly not on licensed product. In India the same phenomenon appears as unlicensed imports and vials sold online; the practical advice is the same — buy from a pharmacy, use the licensed pen, and treat a vial with a hand-written label as a reason to stop and check.
- Ask what device the patient injects from — a multi-dose vial means compounded or unlicensed product
- Inspect any vial for visible particles before use and discard if present
- Class II here means reversible harm is possible; it is not a signal about semaglutide itself
- Report local injection-site reactions in patients using compounded product
- Counsel patients away from online and grey-market supply, which is the underlying problem
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for diabetes & endocrinology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free